Back to Research Hub
Supernus Pharmaceuticals, Inc.
SUPN
$45.66+1.18 (+2.65%)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
StreetsValue research for Supernus Pharmaceuticals, Inc. (SUPN)
Members get the full report for Supernus Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.